Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Wausau Center
483
mi
from 43215
Wausau, WI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Wausau Center
483
mi
from 43215
Wausau, WI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconcin Cancer Center at Aspirus Wausau Hospital
483
mi
from 43215
Wausau, WI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconcin Cancer Center at Aspirus Wausau Hospital
483
mi
from 43215
Wausau, WI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Aurora Women's Pavilion of West Allis Memorial Hospital
333
mi
from 43215
West Allis, WI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Aurora Women's Pavilion of West Allis Memorial Hospital
333
mi
from 43215
West Allis, WI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Diagnostic and Treatment Center
477
mi
from 43215
Weston, WI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Diagnostic and Treatment Center
477
mi
from 43215
Weston, WI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Weston Center
477
mi
from 43215
Weston, WI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Weston Center
477
mi
from 43215
Weston, WI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Wisconsin Rapids Center
460
mi
from 43215
Wisconsin Rapids, WI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Wisconsin Rapids Center
460
mi
from 43215
Wisconsin Rapids, WI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Riverview Uw Cancer Center
460
mi
from 43215
Wisconsin Rapids, WI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Riverview Uw Cancer Center
460
mi
from 43215
Wisconsin Rapids, WI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
1261
mi
from 43215
Sheridan, WY
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
1261
mi
from 43215
Sheridan, WY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
British Columbia Cancer Agency - Centre for the Southern Interior
1888
mi
from 43215
Kelowna,
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
British Columbia Cancer Agency - Centre for the Southern Interior
1888
mi
from 43215
Kelowna,
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
North Broward Medical Center
960
mi
from 43215
Deerfield Beach, FL
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
North Broward Medical Center
960
mi
from 43215
Deerfield Beach, FL
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute at Emory University
432
mi
from 43215
Atlanta, GA
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute at Emory University
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kapiolani Medical Center at Pali Momi
4502
mi
from 43215
'Aiea, HI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center at Pali Momi
4502
mi
from 43215
'Aiea, HI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Regional Health Center
335
mi
from 43215
Mount Vernon, IL
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Regional Health Center
335
mi
from 43215
Mount Vernon, IL
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Union Hospital Cancer Program at Union Hospital
382
mi
from 43215
Elkton, MD
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Union Hospital Cancer Program at Union Hospital
382
mi
from 43215
Elkton, MD
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lakeland Regional Cancer Care Center - St. Joseph
232
mi
from 43215
Saint Joseph, MI
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lakeland Regional Cancer Care Center - St. Joseph
232
mi
from 43215
Saint Joseph, MI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Regions Hospital - Cancer Care Center
617
mi
from 43215
Saint Paul, MN
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Regions Hospital - Cancer Care Center
617
mi
from 43215
Saint Paul, MN
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
United States Air Force Medical Center - Wright-Patterson
mi
from 43215
Wright-Patterson Air Force Base, OH
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
United States Air Force Medical Center - Wright-Patterson
mi
from 43215
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
328
mi
from 43215
Washington,
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Washington Cancer Institute at Washington Hospital Center
328
mi
from 43215
Washington,
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Washington Cancer Institute at Washington Hospital Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sibley Memorial Hospital
328
mi
from 43215
Washington,
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sibley Memorial Hospital
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Walter Reed Army Medical Center
328
mi
from 43215
Washington,
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Walter Reed Army Medical Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Keesler Air Force Base Medical Center
738
mi
from 43215
Keesler Air Force Base, MS
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Keesler Air Force Base Medical Center
738
mi
from 43215
Keesler Air Force Base, MS
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ocean Medical Center at Meridian Health
469
mi
from 43215
Brick, NJ
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ocean Medical Center at Meridian Health
469
mi
from 43215
Brick, NJ
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Albert Einstein Cancer Center at Albert Einstein College of Medicine
486
mi
from 43215
Bronx, NY
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Albert Einstein Cancer Center at Albert Einstein College of Medicine
486
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mountainview Medical
609
mi
from 43215
Berlin, VT
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mountainview Medical
609
mi
from 43215
Berlin, VT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Memorial Cancer Institute at Memorial Regional Hospital
977
mi
from 43215
Hollywood, FL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Memorial Cancer Institute at Memorial Regional Hospital
977
mi
from 43215
Hollywood, FL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Rush-Copley Cancer Care Center
299
mi
from 43215
Aurora, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Rush-Copley Cancer Care Center
299
mi
from 43215
Aurora, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Joseph Medical Center
316
mi
from 43215
Bloomington, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Joseph Medical Center
316
mi
from 43215
Bloomington, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Graham Hospital
371
mi
from 43215
Canton, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Graham Hospital
371
mi
from 43215
Canton, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital
428
mi
from 43215
Carthage, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital
428
mi
from 43215
Carthage, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Anthony's Memorial Hospital
300
mi
from 43215
Effingham, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Anthony's Memorial Hospital
300
mi
from 43215
Effingham, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Eureka Community Hospital
333
mi
from 43215
Eureka, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Eureka Community Hospital
333
mi
from 43215
Eureka, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Galesburg Clinic, PC
391
mi
from 43215
Galesburg, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Galesburg Clinic, PC
391
mi
from 43215
Galesburg, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Galesburg Cottage Hospital
391
mi
from 43215
Galesburg, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Galesburg Cottage Hospital
391
mi
from 43215
Galesburg, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
InterCommunity Cancer Center of Western Illinois
392
mi
from 43215
Galesburg, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
InterCommunity Cancer Center of Western Illinois
392
mi
from 43215
Galesburg, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mason District Hospital
371
mi
from 43215
Havana, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mason District Hospital
371
mi
from 43215
Havana, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Hopedale Medical Complex
339
mi
from 43215
Hopedale, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Hopedale Medical Complex
339
mi
from 43215
Hopedale, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Joliet Oncology-Hematology Associates, Limited - West
288
mi
from 43215
Joliet, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Joliet Oncology-Hematology Associates, Limited - West
288
mi
from 43215
Joliet, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
McDonough District Hospital
404
mi
from 43215
Macomb, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
McDonough District Hospital
404
mi
from 43215
Macomb, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
405
mi
from 43215
Moline, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
405
mi
from 43215
Moline, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
404
mi
from 43215
Moline, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
404
mi
from 43215
Moline, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
BroMenn Regional Medical Center
316
mi
from 43215
Normal, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
BroMenn Regional Medical Center
316
mi
from 43215
Normal, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Community Cancer Center
316
mi
from 43215
Normal, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Community Cancer Center
316
mi
from 43215
Normal, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
OSF Saint Elizabeth Medical Center
319
mi
from 43215
Ottawa, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
OSF Saint Elizabeth Medical Center
319
mi
from 43215
Ottawa, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Associates of Central Illinois, PC - Ottawa
319
mi
from 43215
Ottawa, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Associates of Central Illinois, PC - Ottawa
319
mi
from 43215
Ottawa, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Cancer Treatment Center at Pekin Hospital
350
mi
from 43215
Pekin, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Cancer Treatment Center at Pekin Hospital
350
mi
from 43215
Pekin, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Proctor Hospital
350
mi
from 43215
Peoria, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Proctor Hospital
350
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
OSF St. Francis Medical Center
349
mi
from 43215
Peoria, IL
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
OSF St. Francis Medical Center
349
mi
from 43215
Peoria, IL
Click here to add this to my saved trials